WEBULL
WebtradeDownload

What AtriCure (ATRC)'s First Dual-Energy PFA–RFA Procedures Mean For Shareholders

Simply Wall St · 12/23/2025 17:13
  • AtriCure recently reported successful first-in-human procedures at Australia’s Victorian Heart Hospital using its new dual energy platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, achieving box lesions isolating the pulmonary veins and left atrial posterior wall in under 60 seconds with confirmed acute electrical isolation.
  • This early clinical experience suggests AtriCure is working to extend its long-established Isolator Synergy ablation franchise by pairing radiofrequency’s safety record with the speed and efficiency of pulsed field technology, although the new platform still requires further trials and regulatory approvals.
  • We’ll now examine how this dual energy PFA–RFA innovation could influence AtriCure’s existing investment narrative built around minimally invasive cardiac devices.

AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

AtriCure Investment Narrative Recap

To own AtriCure, you need to believe that its specialized cardiac and pain-management tools can translate growing procedure volumes into sustainable profitability, despite ongoing losses and competition in minimally invasive ablation. The new dual energy PFA–RFA platform directly targets the key near term risk that PFA catheters erode AtriCure’s surgical ablation franchise, but it remains very early stage and does not meaningfully change the core catalysts until larger trials and approvals are in place.

The most relevant recent announcement is the launch of the BoxX-NoAF IDE trial, which seeks to broaden indications for the EnCompass clamp and AtriClip platform by reducing post-operative and long-term atrial fibrillation. Together with the dual energy PFA–RFA work, it reinforces that AtriCure’s main potential upside still hinges on turning innovation and clinical evidence into wider adoption and improved margins, while balancing the heavy R&D spend required to run these programs.

Yet while innovation is encouraging, investors should be aware that rising PFA catheter adoption could still pressure AtriCure’s core surgical ablation revenue if the dual energy platform fails to...

Read the full narrative on AtriCure (it's free!)

AtriCure’s narrative projects $717.8 million revenue and $13.2 million earnings by 2028. This requires 12.8% yearly revenue growth and a $49.6 million earnings increase from -$36.4 million today.

Uncover how AtriCure's forecasts yield a $50.00 fair value, a 20% upside to its current price.

Exploring Other Perspectives

ATRC Earnings & Revenue Growth as at Dec 2025
ATRC Earnings & Revenue Growth as at Dec 2025

Simply Wall St Community members currently see AtriCure’s fair value anywhere between about US$1 and US$50, based on only 2 independent models. Against that wide spread, the central catalyst remains whether new platforms and trials can offset competitive and cost pressures and move the business toward sustained profitability.

Explore 2 other fair value estimates on AtriCure - why the stock might be worth as much as 20% more than the current price!

Build Your Own AtriCure Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.